» Articles » PMID: 34527552

Relationship Between Anti-acetylcholine Receptor Antibodies and the Development of Post-thymectomy Myasthenia Gravis in Patients with Thymoma: a Single-center Experience

Abstract

Background: Approximately 15-29.6% of patients with thymoma have myasthenia gravis (MG). Some of these patients develop MG after thymectomy despite having no history of MG or related symptoms. Few previous studies have examined the risk factors for the development of post-thymectomy MG in patients with thymoma. Herein, we retrospectively reviewed our institutional experience with patients with thymoma who developed MG after thymectomy.

Methods: Twenty-six patients with thymoma but without MG, who were tested preoperatively for anti-acetylcholine receptor antibody (anti-AChR-Ab) levels, underwent surgical resection at our hospital between 2013 and 2020. Patients with thymic carcinoma were excluded from the study. We evaluated the association of outcomes with preoperative anti-AChR-Ab levels and post-thymectomy MG. We performed a χ test for bivariate analysis of categorical data. Differences were considered significant at P<0.05.

Results: The characteristics of the 26 patients (median age: 62 years; 8 men, 18 women) were as follows: World Health Organization (WHO) classifications AB (n=8), B1 (n=9), B2 (n=6), B3 (n=1), and others (n=2) and Masaoka stage I (n=12), II (n=9), III (n=3), and IVa (n=2). Among the 26 patients, only five had high (>0.3 nmol/L) preoperative anti-AChR-Ab levels. Post-thymectomy MG occurred in two of the five patients (40%) with high preoperative anti-AChR-Ab levels. A high preoperative serum anti-AChR-Ab titer was significantly associated with post-thymectomy MG (P=0.0267). The anti-AChR-Ab titer was also measured postoperatively in four of the five (80%) patients with high preoperative levels. The anti-AChR-Ab titer decreased in two of these four patients, and neither developed postoperative MG.

Conclusions: Preoperative and postoperative anti-AChR-Ab positivity might be associated with post-thymectomy MG. Therefore, regular measurement of anti-AChR-Ab levels after thymectomy is required.

Citing Articles

Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.

Huang E, Wu M, Wang T, Huang T, Li Y, Lee C Aging Dis. 2023; 14(4):1070-1092.

PMID: 37163445 PMC: 10389825. DOI: 10.14336/AD.2022.1215.


Thymoma and Myasthenia Gravis: An Examination of a Paraneoplastic Manifestation.

Itani M, Goldman Gollan Y, Ezell K, Mohanna M, Sabbagh S, Mears C Cureus. 2023; 15(2):e34828.

PMID: 36919063 PMC: 10008435. DOI: 10.7759/cureus.34828.


Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis.

Tang M, Shao Y, Dong J, Gao X, Wei S, Ma J Front Oncol. 2023; 13:1061264.

PMID: 36845745 PMC: 9944936. DOI: 10.3389/fonc.2023.1061264.

References
1.
Kondo K, Monden Y . Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg. 2004; 79(1):219-24. DOI: 10.1016/j.athoracsur.2004.06.090. View

2.
Shen J, Tie H, Xu A, Chen D, Ma D, Zhang B . Inter-relationship among myasthenia gravis, WHO histology, and Masaoka clinical stage and effect on surgical methods in patients with thymoma: a retrospective cohort study. J Thorac Dis. 2018; 10(5):2981-2990. PMC: 6006062. DOI: 10.21037/jtd.2018.05.30. View

3.
Imanishi N, Nabe Y, Takenaka M, Hirai A, Ichiki Y, Tanaka F . Extended pleurectomy decortication for thymoma with pleural dissemination. Gen Thorac Cardiovasc Surg. 2018; 67(9):814-817. DOI: 10.1007/s11748-018-1037-4. View

4.
Kondo K, Monden Y . Myasthenia gravis appearing after thymectomy for thymoma. Eur J Cardiothorac Surg. 2005; 28(1):22-5. DOI: 10.1016/j.ejcts.2005.03.039. View

5.
Hoffacker V, Schultz A, Tiesinga J, Gold R, Schalke B, Nix W . Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000; 96(12):3872-9. View